Category: Covid-19

Governments Often Deliver “Horrible Ideas Executed Terribly”

(p. A15) After the $320 million floating fiasco ran aground, Ohio Sen. J.D. Vance tweeted: “The Gaza pier is a symbol of the Biden administration. A horrible idea executed terribly.”

. . .

Government is bad for your health. Whose idea was it to pay for gain-of-function research in Wuhan? Remember when the Food and Drug Administration delayed the rollout of Covid tests by, among other things, requiring applications on CD-ROMs? In 2020! The FDA interference, according to a Yale Law Journal 2020 Forum, was “possibly the deadliest regulatory overreach in U.S. history.”

. . .

Between the Covid-19 Economic Injury Disaster Loan, the Paycheck Protection Program and the Federal Pandemic Unemployment Compensation program, the FBI reports almost $300 billion in fraud. It was so easy, tens of thousands reportedly filed applications from jail.

. . .

Why are governments so bad at execution? Accountability and incentives. There are no prices or profits, just elusive cost benefits estimated in simple spreadsheets any first-year investment banker could fudge.

But these public-works projects are well intentioned, right? Hardly. Good luck finding all the hidden agendas, political back scratching and paid-off donors. Or, in the case of student loans, bribes to voters. Getting re-elected is how politicians measure the success of government work vs. private-sector profits.

Those profits from each private-sector project or product provide capital that pays for the next important project. In perpetuity. Profits also provide guidance to markets that fund great ideas and kill off bad ones. It’s Darwinism vs. kleptocracy. Sadly, politicians and industrial policy will always fund dumb things like electric-vehicle chargers, high-speed rail and Neom—horrible ideas executed terribly.

For the full commentary see:

Andy Kessler. “Your Government at Work.” The Wall Street Journal (Monday, June 10, 2024): A15.

(Note: ellipses added.)

(Note: the online version of the commentary has the date June 9, 2024, and has the same title as the print version.)

In “An Entrenched Echo Chamber” the Highly Credentialed Slow Progress Toward an Alzheimer’s Cure

Centralized research funding (often centralized by government agencies) reduces the pluralism of ideas and methods that often lead to breakthrough innovations. The story of Alzheimer’s research, quoted below, is a dramatic case-in-point.

A secondary related lesson from the story quoted below is that Dr. Thambisetty, one of the outsiders struggling to make a difference, is trying to evade the enormous costs of mandated phase 3 clinical trials, by only investigating drugs that already have been approved by the FDA for use against other conditions. With his severely limited funding, and the huge costs of mandated phase 3 clinical trials, this may be a shrewd strategy for Thambisetty, but notice that by following it, he will never explore all the as-yet-unapproved chemicals that might include the best magic bullet against Alzheimer’s.)

(p. A25) What if a preposterous failed treatment for Covid-19 — the arthritis drug hydroxychloroquine — could successfully treat another dreaded disease, Alzheimer’s?

Dr. Madhav Thambisetty, a neurologist at the National Institute on Aging, thinks the drug’s suppression of inflammation, commonly associated with neurodegenerative disorders, might provide surprising benefits for dementia.

It’s an intriguing idea. Unfortunately, we won’t know for quite a while, if ever, whether Dr. Thambisetty is right. That’s because unconventional ideas that do not offer fealty to the dominant approach to study and treat Alzheimer’s — what’s known as the amyloid hypothesis — often find themselves starved for funds and scientific mind share.

Such shortsighted rigidity may have slowed progress toward a cure — a tragedy for a disease projected to affect more than 11 million people in the United States by 2040.

. . .

. . ., in 2006, an animal experiment published in the journal Nature identified a specific type of amyloid protein as the first substance found in brain tissue to directly cause symptoms associated with Alzheimer’s. Top scientists called it a breakthrough that provided a key target for treatments. The paper became one of the most cited in the field, and funds to explore similar proteins skyrocketed.

. . .

In 2022, my investigation in Science showed evidence that the famous 2006 experiment that helped push forward the amyloid hypothesis used falsified data. On June 24 [2024], after most of its authors conceded technical images were doctored, the paper was finally retracted.

. . .

In reporting for my forthcoming book about the disturbing state of play in Alzheimer’s research, I’ve spoken to many scientists pursuing alternatives. Dr. Thambisetty, for example, compares brain tissues from people who died in their 30s or 40s with and without genetic risk factors for Alzheimer’s. He then compares these findings to tissues from deceased Alzheimer’s patients and people who didn’t have the disease. Where changes overlap, drug targets might emerge. Rather than develop new drugs through lab and animal testing, followed by clinical trials that cost vast sums — a process that can take decades — he examines treatments already approved as reasonably safe and effective for other conditions. Patent protections have lapsed for many, making them inexpensive.

Experiments have also begun to test the weight-loss drug semaglutide (sold as Wegovy, among other brands). Researchers hope that results due in 2026 will show that its anti-inflammatory effects — like Dr. Thambisetty’s idea about hydroxychloroquine — slow cognitive decline.

Ruth Itzhaki, a research scientist at the University of Oxford, stirred curiosity in the 1990s when she shared evidence tying Alzheimer’s to herpesvirus — a scourge spread by oral or genital contact and often resulting in painful infections. For years, powerful promoters of the amyloid hypothesis ignored or dismissed the infection hypothesis for Alzheimer’s, effectively rendering it invisible, Dr. Itzhaki said with exasperation. Research suggests that viruses may hide undetected in organs, including the brain, for years, causing symptoms divergent from the original infection.

. . .

Sometimes a disease stems from a single clear-cut origin, such as genetic mutations that cause deadly sickle cell disease. “But very few diseases of aging have just one cause. It’s just not logical,” said Dr. Matthew Schrag, a neurologist at Vanderbilt University Medical Center. Working independently of his university, he discovered the 2006 research image manipulations.

. . .

“There is an entrenched echo chamber that involves a lot of big names,” Dr. Schrag said. “It’s time for the field to move on.”

For the full commentary see:

Charles Piller. “All the Alzheimer’s Research We Didn’t Do.” The New York Times (Friday, July 12, 2024): A25.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the commentary has the date July 7, 2024, and has the same title as the print version. Where there are a couple of small differences in wording, the passages quoted above follow the online version.)

Piller’s paper in Science, mentioned above, is:

Piller, Charles. “Blots on a Field?” Science 377, no. 6604 (July 2022): 358-63.

Piller’s commentary is related to his forthcoming book:

Piller, Charles. Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s. New York: Atria/One Signal Publishers, Forthcoming on February 4, 2025.

Subpoena Emails Between Wuhan Lab and U.S. Partners to Illuminate Origin of Covid

The passages quoted below are a very small part of a much longer essay that took up the space of a full page and a half of the SundayOpinion section of The New York Times.

(p. 6) On Monday [June 3, 2024], Dr. Anthony Fauci returned to the halls of Congress and testified before the House subcommittee investigating the Covid-19 pandemic. He was questioned about several topics related to the government’s handling of Covid-19, including how the National Institute of Allergy and Infectious Diseases, which he directed until retiring in 2022, supported risky virus work at a Chinese institute whose research may have caused the pandemic.

For more than four years, reflexive partisan politics have derailed the search for the truth about a catastrophe that has touched us all. It has been estimated that at least 25 million people around the world have died because of Covid-19, with over a million of those deaths in the United States.

Although how the pandemic started has been hotly debated, a growing volume of evidence — gleaned from public records released under the Freedom of Information Act, digital sleuthing through online databases, scientific papers analyzing the virus and its spread, and leaks from within the U.S. government — suggests that the pandemic most likely occurred because a virus escaped from a research lab in Wuhan, China. If so, it would be the most costly accident in the history of science.

. . .

(p. 7) The pandemic could have been caused by any of hundreds of virus species, at any of tens of thousands of wildlife markets, in any of thousands of cities, and in any year. But it was a SARS-like coronavirus with a unique furin cleavage site that emerged in Wuhan, less than two years after scientists, sometimes working under inadequate biosafety conditions, proposed collecting and creating viruses of that same design.

While several natural spillover scenarios remain plausible, and we still don’t know enough about the full extent of virus research conducted at the Wuhan institute by Dr. Shi’s team and other researchers, a laboratory accident is the most parsimonious explanation of how the pandemic began.

Given what we now know, investigators should follow their strongest leads and subpoena all exchanges between the Wuhan scientists and their international partners, including unpublished research proposals, manuscripts, data and commercial orders. In particular, exchanges from 2018 and 2019 — the critical two years before the emergence of Covid-19 — are very likely to be illuminating (and require no cooperation from the Chinese government to acquire), yet they remain beyond the public’s view more than four years after the pandemic began.

Whether the pandemic started on a lab bench or in a market stall, it is undeniable that U.S. federal funding helped to build an unprecedented collection of SARS-like viruses at the Wuhan institute, as well as contributing to research that enhanced them.

. . .

A thorough investigation by the U.S. government could unearth more evidence while spurring whistleblowers to find their courage and seek their moment of opportunity. It would also show the world that U.S. leaders and scientists are not afraid of what the truth behind the pandemic may be.

For the full essay see:

Alina Chan. “Why Covid Probably Started in a Lab.” The New York Times, SundayOpinion Section (Sunday, June 9, 2024): 6-7.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the essay has the date June 3, 2024, and has the title “Why the Pandemic Probably Started in a Lab, in 5 Key Points.”)

The essay quoted above summarizes and updates her co-authored book:

Chan, Alina, and Matt Ridley. Viral: The Search for the Origin of Covid-19. New York: Harper, 2021.

Many Workers Happily Accept Lower Pay if They Can Work Remotely

(p. A15) The U.S. inflation rate tumbled from June 2022 to June 2023. It was no slide down the Phillips curve of the sort that textbooks attribute to tighter monetary policy. Instead, inflation fell 6 percentage points as unemployment stayed low. It is thus a mistake to credit this episode to the Federal Reserve’s departure from low interest rates.

. . .

Employees initially reaped the benefits of remote work, because their wages reflected pre-pandemic conditions and expectations. Over time, pay adjusted and employers adapted, eventually allowing them to benefit from slower wage growth.

My research quantifies this source of wage-growth moderation. Along with the Atlanta Fed, our team asked hundreds of business executives whether remote work affected their firms’ wages. Thirty-eight percent told us their companies had relied on the work-from-home boom to moderate wage-growth pressures in the previous 12 months. Forty-one percent said their firms planned to use remote work to restrain wage growth in the next 12 months. We found that the boom reduced overall wage growth by 2 percentage points from spring 2021 to spring 2023. In all likelihood, the effects extended beyond this interval, because pay adjusts slowly.

Remote work cuts costs in other ways, too. When employees work on site only two days a week, their companies need less space.

For the full commentary see:

Steven J. Davis. “Working at Home Helped Whip Inflation.” The Wall Street Journal (Thursday, June 20, 2024): A15.

(Note: ellipsis added.)

(Note: the online version of the commentary has the date June 19, 2024, and has the same title as the print version.)

Davis’s research mentioned above is:

Barrero, Jose Maria, Nicholas Bloom, Steven J. Davis, Brent H. Meyer, and Emil Mihaylov. “The Shift to Remote Work Lessens Wage-Growth Pressures.” National Bureau of Economic Research Working Paper # 30197, July 2022.

“Extended School Closures Did Not Significantly Stop the Spread of Covid, While the Academic Harms for Children Have Been Large and Long-Lasting”

(p. A13) Four years ago this month, schools nationwide began to shut down, igniting one of the most polarizing and partisan debates of the pandemic.

Some schools, often in Republican-led states and rural areas, reopened by fall 2020. Others, typically in large cities and states led by Democrats, would not fully reopen for another year.

A variety of data — about children’s academic outcomes and about the spread of Covid-19 — has accumulated in the time since. Today, there is broad acknowledgment among many public health and education experts that extended school closures did not significantly stop the spread of Covid, while the academic harms for children have been large and long-lasting.

For the full story see:

Sarah Mervosh, Claire Cain Miller and Francesca Paris. “Pandemic School Closures Came at a Steep Cost to Students, Data Shows.” The New York Times (Friday, March 29, 2024): A13.

(Note: the online version of the story was updated March 19, 2024, and has the title “What the Data Says About Pandemic School Closures, Four Years Later.”)

The Cholera and Bubonic Plague Vaccination Campaigns of Waldemar Haffkine Count as Evidence of “the Benevolence of British Medical Imperialism”

(p. C7) “In the end, all history is natural history,” writes Simon Schama in “Foreign Bodies: Pandemics, Vaccines and the Health of Nations.” The author, a wide-ranging historian and an engaging television host, reconciles the weight of medical detail with the light-footed pleasures of narrative discovery. His book profiles some of the unsung miracle workers of modern vaccination, and offers a subtle rumination on borders political and biological.

. . .

Inoculation, Mr. Schama writes, became a “serious big business” in commercial England, despite the inoculators’ inability to understand how (p. C8) it worked, and despite Tory suspicions that the procedure meant “new-fangled,” possibly Jewish, interference in the divine plan. In 1764, the Italian medical professor Angelo Gatti published an impassioned defense of inoculation that demolished humoral theory. Mr. Schama calls Gatti an “unsung visionary of the Enlightenment.” His work was a boon to public health, though his findings met resistance in France, where the prerevolutionary medical establishment was more concerned with protecting its authority.

. . .

(p. C8) Mr. Schama alights on the story of Waldemar Haffkine, the Odessa-born Jew who created vaccines against cholera and bubonic plague. In 1892, Haffkine inoculated himself against cholera with the vaccine he had developed at the Institut Pasteur in Paris. He went on to inoculate thousands of Indians, and so effectively that his campaigns served as, in Mr. Schama’s words, “an advertisement for the benevolence of British medical imperialism.”

. . .

The author notes the contrast between the facts of Haffkine’s achievements and the response of the British establishment, with its modern echoes of the medieval fantasy that Jews were “demonic instigators of mass death.” Yet Mr. Schama’s skepticism of authority only extends so far. It would have been instructive to learn why, when Covid-19 appeared, the WHO concurred with Voltaire that the Chinese were “the wisest and best governed people in the world” and advised liberal democracies to emulate China’s lockdowns.

Haffkine’s colleague Ernest Hanbury Hankin once wrote an essay called “The Mental Limitations of the Expert.” Mr. Schama’s conclusion shows the limitations of our expert class, which appears not to understand the breach of public trust caused by the politicization of Covid policy and the suppression of public debate. You do not have to be “far right” to distrust mandatory mRNA vaccination. As Mr. Schama shows, the health of the body politic depends on scientific inquiry.

For the full review, see:

Dominic Green. “Protecting the Body Politic.” The Wall Street Journal (Saturday, Sept. 23, 2023): C7-C8.

(Note: ellipses added.)

(Note: the online version of the review has the date September 22, 2023, and has the title “‘Foreign Bodies’ Review: Migrant Microbes, Human Borders.”)

The book under review is:

Schama, Simon. Foreign Bodies: Pandemics, Vaccines, and the Health of Nations. New York: Ecco Press, 2023.

Fauci’s Office Rejected Protocol for a Voluntary COVID Human Challenge Trial That Could Have Tested Therapies and Vaccines Faster

(p. 2) . . . the first Covid-19 human challenge study [was] just completed in Britain, where young, healthy and unvaccinated volunteers were infected with the coronavirus that causes Covid while researchers carefully monitored how their bodies responded.

. . ., there were those who decried deliberately infecting or “challenging” healthy volunteers with disease-causing pathogens. It violates the medical principle of “do no harm.” The trade-off is a unique opportunity to discover the causes, transmission and progression of an illness, as well as the ability to more rapidly test the effectiveness of proposed treatments.

. . .

Dr. [Matthew] Memoli [the director of the Laboratory of Infectious Diseases Clinical Studies Unit at the National Institute of Allergy and Infectious Diseases] has conducted numerous influenza challenge studies, and he prepared a protocol for a Covid challenge trial that the National Institute of Allergy and Infectious Diseases rejected last year because it was felt that not enough was known about the virus and that there were no effective rescue therapies, according to a statement from the office of the director, Dr. Anthony Fauci.

The consortium formed to run Britain’s Covid challenge trial, which included scientists who trained at the Common Cold Unit, had access to the British National Health Service’s robust, real-time data on Covid hospitalizations and deaths. The researchers designing the study said they felt confident that there was little risk to the healthy unvaccinated 18-to-30-year-old volunteers they recruited for the trial. There were no severe adverse events in the 36 people who participated, and they will continue to be monitored over the next year.

The aim of the study was to identify the lowest amount of virus to safely and reliably infect someone, so researchers can later easily test the efficacy of vaccines or antivirals on future challenge trial volunteers.

. . .

Dr. Fauci’s office said the institute has no plans to fund Covid-19 human challenge trials in the future. Many bioethicists support that decision. “We don’t ask people to sacrifice themselves for the good of society,” said Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics. “In the U.S., we are very much about protecting individual rights and individual life and health and liberty, while in more communal societies it’s about the greater good.”

But Josh Morrison, a co-founder of 1Day Sooner, which advocates on behalf of more than 40,000 would-be human challenge volunteers, argues it should be his and other people’s right to take risks for the greater good. “Most people aren’t going to want to be in a Covid challenge study, and that’s totally fine, but they shouldn’t project their own choices on other people,” he said.

. . .

As one participant in Britain’s Covid human challenge trial put it: “You know the phrase ‘one interesting fact about yourself’ that strikes terror into everyone? That’s now solved forever. I did something that made a difference.”

For the full commentary, see:

Kate Murphy. “Are Human Challenge Trials Ethical?” The New York Times, SundayReview Section (Sunday, October 17, 2021 [sic]): 2.

(Note: ellipses, and bracketed words, added.)

(Note: the online version of the commentary has the date Oct. 14, 2021 [sic], and has the title “Britain Infected Volunteers With the Coronavirus. Why Won’t the U.S.?”)

Risk of Bat Disease Spillover to Humans Is Small and Decreasing

(p. A15) The World Health Assembly in May is poised to divert $10.5 billion of aid away from tackling diseases such as malaria and tuberculosis. Instead, that money will go toward combating the threat of viruses newly caught from wildlife. The assumption behind this initiative, endorsed by the Group of 20 summit in Bali in 2022, is that the threat of pandemics from spillovers of animal viruses is dramatically increasing.

That assumption is almost certainly false. A new report from the University of Leeds, prepared in part by former World Health Organization executives, finds that the claims made by the G-20 in support of this agenda either are unsupported by evidence, contradict their own cited sources, or fail to correct for improved detection of pathogens. Over the past decade the burden and risk of spillover has been relatively small and probably decreasing. The Leeds authors conclude: “The implication is that the largest investment in international public health in history is based on misinterpretations of key evidence as well as a failure to thoroughly analyze existing data.”

. . .

It is a misconception that population growth or prosperity leads humanity to encroach on wildlife habitats. The poorest people in Africa encroach on forest wildlife by hunting for bush meat; when they grow richer, they shop for chicken or pork instead. Humans visited bat caves more frequently in the distant past.

. . .

The prospect of spending $31 billion a year on pandemic prevention, a third of which would be new money and a third diverted from other programs, provides an incentive for international bureaucrats to ignore or misrepresent evidence that the problem is small.

But a dollar spent on spillover can’t be spent on something else, and the evidence is clear that sanitation, nutrition and vitamins are more cost-effective ways to save lives in poor countries—from infectious diseases as well as other causes.

For the full commentary, see:

Matt Ridley. “Why Scientists Love Chasing Bats.” The Wall Street Journal (Thursday, March 7, 2024): A15.

(Note: ellipses added.)

(Note: the online version of the commentary has the date March 6, 2024, and has the same title as the print version.)

The University of Leeds report mentioned above is:

Bell, David, Garrett Brown, Blagovesta Tacheva, and Jean von Agris. “Rational Policy over Panic: Re-Evaluating Pandemic Risk within the Global Pandemic Prevention, Preparedness and Response Agenda.” REPPARE Report. University of Leeds, UK, Feb. 2024, URL: https://essl.leeds.ac.uk/downloads/download/228/rational-policy-over-panic.

If Your Disease Has No “F.D.A.-Stamped” Cure, Try Rational Experiments Rather Than Give Up

(p. 9) My whole family was sick in March with Covid-like symptoms, and though the one test we obtained was negative, I’m pretty sure we had the thing itself — and my own symptoms took months rather than weeks to disappear.

But unlike many of the afflicted, I didn’t find the experience particularly shocking, because I have a prior long-haul experience of my own. In the spring of 2015, I was bitten by a deer tick, and the effects of the subsequent illness — a combination of Lyme disease and a more obscure tick-borne infection, Bartonella — have been with me ever since.

Lyme disease in its chronic form — or, per official medical parlance, “post-treatment Lyme disease syndrome” — is a fiendishly complicated and controversial subject, and what I learned from the experience would (and will, at some point) fill a book.

. . .

If you feel like you need something else to get better, some outside intervention, something more than just your own beleaguered body’s resources, be impatient — and find a way to go in search of it.

. . .

EXPERIMENT, EXPERIMENT, EXPERIMENT.

There is no treatment yet for “long haul” Covid that meets the standard of a randomized, double-blind, placebo-controlled trial, which means that the F.D.A.-stamped medical consensus can’t be your only guide if you’re trying to break a systemic, debilitating curse. The realm beyond that consensus has, yes, plenty of quacks, perils and overpriced placebos. But it also includes treatments that may help you — starting with the most basic herbs and vitamins, and expanding into things that, well, let’s just say I wouldn’t have ever imagined myself trying before I become ill myself.

So please don’t drink bleach, or believe everything you read on Goop.com. But if you find yourself decanting Chinese tinctures, or lying on a chiropractor’s table with magnets placed strategically around your body, or listening to an “Anti-Coronavirus Frequency” on Spotify, and you think, how did I end up here?, know that you aren’t alone, and you aren’t being irrational. The irrational thing is to be sick, to have no official treatment available, and to fear the outré or strange more than you fear the permanence of your disease.

. . .

. . . I believe that with enough time and experimentation, I will actually be well.

That belief is essential. Hold on to it. In the long haul, it may see you through.

For the full commentary, see:

Ross Douthat. “What to Do When Covid Doesn’t Go Away.” The New York Times, SundayReview Section (Sunday, August 9, 2020 [sic]): 9.

(Note: ellipses and bracketed year added. A few words in the original are italicized, but you cannot see that since my blog formatting has all quoted words italicized.)

(Note: the online version of the commentary has the date Aug. 8, 2020 [sic], and has the title “China Wants to Move Ahead, but Xi Jinping Is Looking to the Past.” The heading EXPERIMENT, EXPERIMENT, EXPERIMENT was in bold in both the online and print versions. In the print version it was all in caps. In the online version only the first letter of each word was capitalized.)

Douthat’s The Deep Places book can be viewed as a substantial elaboration of the commentary quoted above:

Douthat, Ross. The Deep Places: A Memoir of Illness and Discovery. New York: Convergent Books, 2021.

All Conclusions in Science Are Open to Further Inquiry

(p. C3) Victory is often temporary. In December 2014, a nurse named Nina Pham contracted Ebola from a patient in Dallas. She was transferred to the National Institutes of Health in Bethesda, Md., and treated by a team led by Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

When Ms. Pham was discharged, the cameras captured an indelible moment: Together with NIH Director Francis Collins, Dr. Fauci, dressed in a crisp white lab coat, walked her out with his arm draped over her shoulder. This conveyed a critical message at a time when public fear about the disease was widespread. “We would not be releasing Ms. Pham if we were not completely confident in the knowledge that she has fully recovered, is virus free and poses no public health threat,” an NIH statement read.

But scientific certainty often carries an asterisk. Six months later, doctors in Atlanta discovered that in some patients who survive, the Ebola virus could still be found hidden away in parts of the body. This did not indicate that they could transmit the disease, but it meant that they could no longer be declared “virus-free” with certainty. This episode demonstrated how quickly our knowledge about public health threats can alter. What we once thought was true for the Ebola virus had changed, and no doubt will continue to evolve.

For the full commentary, see:

Jeremy Brown. “What Past Crises Tell Us About the Coronavirus.” The Wall Street Journal (Saturday, Feb. 1, 2020 [sic]): C3.

(Note: the online version of the commentary was updated Jan. 31, 2020 [sic], and has the same title as the print version. In both the online and print versions, the first sentence quoted above is in bold font.)

In Managing Workers Firms Should “Experiment with New Forms of Freedom”

(p. C1) In a classic 1958 lecture, the philosopher Isaiah Berlin distinguished between two types of freedom. Negative liberty is freedom from obstacles and interference by others. Positive liberty is freedom to control your own destiny and shape your own life. If we want to maximize net freedom in the future of work, we need to expand both positive and negative liberty.

The debate about whether work should be in-person, remote-first or hybrid is too narrow. Yes, people want the freedom to decide where they work. But they also want the freedom to decide who they work with, what they work on and when they work. Real flexibility is having autonomy to choose your people, your purpose and your priorities.

. . .

(p. C2) We need boundaries to protect individual focus time too.

. . .

One effective strategy seems to be blocking quiet time in the mornings as a window for deep work, and then coming together after lunch. When virtual meetings are held in the afternoon, people are less likely to multitask—probably in part because they’ve been able to make progress on their own tasks.

. . .

Flexible work is here to stay, but companies that resist it may not be. One of the biggest mistakes I saw companies make before Covid was failing to experiment with new forms of freedom.

For the full commentary, see:

Adam Grant. “The Real Meaning of Freedom at Work.” The Wall Street Journal (Saturday, Oct. 9, 2021 [sic]): C1-C2.

(Note: ellipses added.)

(Note: the online version of the commentary was updated October 8, 2021 [sic], and has the same title as the print version.)